Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...

Short interest in Stoke Therapeutics Inc (NASDAQ:STOK) increased during the last reporting period, rising from 11.72M to 13.91M. This put 23.23% of the company's publicly available shares short. Based ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Market Context Stoke (STOK) market analysis \| growth forecasts and trading activity remain in focus. Many traders have ...

The average one-year price target for Stoke Therapeutics (NasdaqGS:STOK) has been revised to $36.46 / share. This is an increase of 10.42% from the prior estimate of $33.02 dated December 18, 2025.

Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...

) has been revised to $43.96 / share. This is an increase of 12.11% from the prior estimate of $39.21 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...